The integrin b 4 subunit has been shown to be involved in various aspects of cancer progression. The aim of the present work was to evaluate the expression of b 4 in primary colon cancers and to investigate the occurrence of a previously identified intestinal nonfunctional variant of b 4 (b 4 ctdÀ ) for adhesion to laminin. Immunodetection of b 4 using a panel of antibodies and RT-PCR analyses were performed on series of paired primary colon tumors and corresponding resection margins. The b 4 subunit was found to be significantly overexpressed in cancer specimens at both the protein and transcript levels. Surprisingly, b 4 levels of expression were closely correlated with those of the oncogene c-Myc in individual specimens. In vitro studies of c-Myc overexpression showed an upregulation of b 4 promoter activity. Finally, the b 4 ctdÀ form was identified in the normal proliferative colonic cells but was found to be predominantly absent in colon cancer cells, both in situ and in vitro. We concluded that the b 4 ctdÀ form is lost from colon cancer cells, while the level of the wildtype form of b 4 , which is functional for adhesion to laminin, is increased in primary tumors in relation with the expression of c-Myc. Oncogene (2005) 24, 6820-6829.
Introduction
Integrins are a class of transmembrane ab heterodimeric molecules that function as specific adhesion receptors for extracellular matrix molecules (Hynes, 2002) . Through their generally short cytoplasmic domains, the integrins provide links to the actin cytoskeleton and regulate intracellular signaling activities of importance for proliferation, migration and survival (Giancotti and Ruoslahti, 1999a) . Integrins do not possess intrinsic kinase activity, but stimulate intracellular signalization via recruitment of adaptor proteins and nonreceptor tyrosine kinases (Giancotti and Ruoslahti, 1999a; Liu et al., 2000; Hynes, 2002; Miranti and Brugge, 2002) .
Epithelial cells of different types express the integrin b 4 subunit (Beaulieu, 1999; Borradori and Sonnenberg, 1999; Watt, 2002) , which differs from other and more ubiquitous b integrin subunits by a large cytoplasmic domain, which predominantly interacts with the intermediate filament network rather than with the actin network . The integrin b 4 subunit participates in the formation of a single functional dimer: the a 6 b 4 integrin. Ligation of a 6 b 4 to its main ligand, laminin, leads to activation of the intracellular signalization pathways of Ras and PI3-K, both of importance for proliferation, migration, differentiation and/or survival (Giancotti and Ruoslahti, 1999b; Dans et al., 2001; Gauthier et al., 2001; . Much of the function of the a 6 b 4 integrin can be attributed to interactions mediated by its b 4 cytoplasmic domain (LaFlamme et al., 1997; Giancotti and Ruoslahti, 1999a) . As for its a 6 partner (de Melker and Sonnenberg, 1999) , the b 4 subunit is subject to alternative mRNA splicing leading to cytoplasmic splice variants (Hogervorst et al., 1990; Suzuki and Naitoh, 1990; Tamura et al., 1990; Clarke et al., 1994; van Leusden et al., 1997) . While these variants have been found to be expressed together with the original and most abundant b 4 A form, they are still poorly characterized from a functional point of view (de Melker and Sonnenberg, 1999) . On the other hand, we have recently described another cytoplasmic variant of the b 4 A subunit that results from the proteolytic cleavage of the C-terminal domain (ctd) in undifferentiated human intestinal cells (Basora et al., 1999) . This variant lacks the final COOHterminal part of the cytoplasmic domain and is referred to as b 4 ctdÀ . Interestingly, the b 4 ctdÀ variant was found to be associated with the epithelial cells of the proliferative compartment of the crypts while the full-length b 4 (b 4 ctd þ ) was only present in the differentiated cells of the villus. Furthermore, although the b 4 ctdÀ variant appears to heterodimerize normally with the a 6 subunit in intestinal cells, the a 6 b 4 ctdÀ form of the integrin was found to be nonfunctional for adhesion on purified laminin-5, in contrast to the wild-type form (Basora et al., 1999) . An increasing body of in vitro based evidence suggests that b 4 is an important player in cancer progression (for recent reviews, see Guo and Giancotti, 2004) . In vivo, the importance of the integrin a 6 b 4 was recently demonstrated when tumor formation by human epidermal grafts in immunodeficient mice was found to be dependent upon the presence of the integrin b 4 subunit (Dajee et al., 2003) , while another recent study demonstrated the importance for the C-terminal tail (beyond aa 1355) of b 4 for intracellular signaling and subsequent angiogenesis and invasion in endothelial cells (Nikolopoulos et al., 2004) . Another, less direct, line of evidence of the role of the integrin b 4 subunit in cancer progression is the finding that laminin-5, an important ligand for a 6 b 4 , accumulates along the invasive edge of colorectal (Lohi et al., 2000) , pancreatic (Tani et al., 1997) and gastric (Tani et al., 1996) tumors. In colorectal cancers, integrin b 4 subunit expression has been the subject of a number of studies (Stallmach et al., 1992; Falcioni et al., 1994; Sordat et al., 1998; Lohi et al., 2000) . Although these studies report the integrin b 4 subunit to be uniformly expressed at the base of all epithelial cells in the normal epithelium of the colon, the analysis of its expression in malignancies has led to conflicting results. Indeed, expression of the b 4 subunit was found to be reduced/ lost in carcinomas in one study (Stallmach et al., 1992) , maintained in another (Lohi et al., 2000) and heterogeneously increased in a third (Falcioni et al., 1994) . In a fourth study, a differentiation dependent expression pattern was described in which the expression of b 4 was maintained in well-differentiated carcinomas and decreased in moderately and poorly differentiated (PD) carcinomas (Sordat et al., 1998) .
In the present study, we have investigated the expression of the integrin b 4 subunit at both the protein and transcript levels in series of paired human colon cancer primary tumors and corresponding resection margins. We report that the integrin b 4 subunit is upregulated at both the transcript and protein levels in primary tumors and that this upregulation appears to correspond with the expression of the oncogene c-Myc (MYC). Furthermore, we identified the b 4 ctdÀ variant in the proliferative compartment of the normal colonic glands but found that it is predominantly lost in cancer cells, both in situ and in vitro, suggesting a potential relation between the upregulation of a form of b 4 functional for adhesion to laminins and the process of tumor progression.
Results

Expression and distribution of b 4 in normal colonic mucosa and corresponding carcinoma
The expression of b 4 integrin subunit cytoplasmic variants and their distribution at the epithelial-stromal interface was determined by double indirect immunofluorescence staining with specific anti-b 4 antibodies. In histologically normal specimens (resection margins), the b 4 subunit was uniformly detected at the base of the epithelium along the crypt-villus axis with antibodies directed to the extracellular domain (Figure 1a , c). In contrast, an increasing gradient of expression of b 4 from the bottom of the gland to the surface of the epithelium was consistently observed (Figure 1b, c) with antibodies directed to the cytoplasmic terminal domain (ctd), suggesting that, as observed in the small intestine (Basora et al., 1999) , proliferative and less differentiated epithelial cells in the normal colonic glands express a form of b 4 lacking the C-terminal end of the cytoplasmic domain, referred to as b 4 ctdÀ . Indeed, in the merged image (Figure 1c) , the yellow co-staining was replaced by predominantly red staining in the bottom of the gland showing the absence of the ctd epitope.
Microscopic analysis of b 4 expression in carcinomas revealed a higher staining intensity than in the corresponding normal mucosa in a significant proportion of the specimens examined (Figure 1d-h ). An evaluation of staining intensity on a þ /À scale confirmed the overall increase of staining intensity for b 4 in tumors relative to their histologically normal counterparts (P ¼ 0.014, Mann-Whitney rank sum test) (Figure 2a) . b 4 expression level was found to depend upon the stage of the tumor (Figure 2b ), being significantly increased in moderately differentiated (MD) and well differentiated (WD) carcinomas (P ¼ 0.002) while not in the PD specimens. Sucraseisomaltase expression, used as a control for the resection margins, was found to be weakly expressed in a large majority of the histologically normal specimens (not shown), as expected (Beaulieu et al., 1990) .
Loss of the b 4 ctdÀ variant in carcinoma samples
As exemplified in Figure 1d -f (WD adenocarcinomas), b 4 was predominantly found to be expressed as a b 4 ctd þ form in colon tumors, as deduced by the relatively even green staining observed at the base of epithelial cells with the anti-b 4 c antibodies (Figure 1e ), and the predominantly yellow staining of the merged picture ( Figure 1f ). The same predominantly yellow staining was observed in merged images of moderately ( Figure  1g -h) and poorly ( Figure 1i ) differentiated carcinomas. However, some discrete subglandular regions were found to express the b 4 ctdÀ variant (see arrows in Figure 1f and the corresponding lack of staining with the anti-b 4 c antibodies in Figure 1e ). In addition, a complete loss of b 4 staining was rarely observed in MD tumors (see arrowheads in Figure 1g , h) while found more frequently in PD adenocarcinomas (Figure 1i ).
In support of the observations on intact tumors indicating a predominant expression of the wild-type Expression levels of transcripts of the oncogene MYC and the b 1 integrin subunit were also analysed while b-actin was used as control for cDNA input ( Figure 4a ). As expected from previous studies for MYC (Erisman et al., 1985; Smith et al., 1993) and from the above observations for the b 4 protein, relative amounts of both MYC and b 4 subunit transcripts were found to be significantly higher in carcinomas than in corresponding normal specimens (approximately three and two times higher, respectively; Po0.01 and o0.005, paired t-test) relative to b-actin (Figure 4b) , whereas the relative level of the b 1 integrin subunit ( Figure 4b ) did not differ. Further analysis of b 4 and MYC expression in the individual specimens revealed a close correlation between the two transcript levels (r ¼ 0.73, Po0.001; Figure 4c ). The results were re-evaluated and confirmed by realtime RT-QPCR using a larger set of paired specimens (n ¼ 13) as well as another housekeeping gene (RPS14) (Figure 4d-e) . Similar levels of upregulation were found for both the integrin b 4 subunit and MYC in primary colorectal tumors compared to the corresponding resection margins (2.5 and 3.5-fold, respectively, Po0.05; Figure 4d ), while the transcript for the integrin b 1 subunit was not found to be significantly different (not shown). Similar to the initial experiments, we observed a sharp correlation between the transcript amounts of the integrin b 4 subunit and MYC (r ¼ 0.719, Po0.001; Figure 4e ) using the larger set of samples.
MYC stimulates integrin b 4 promoter activity
The observed correlation between MYC and b 4 transcript levels prompted us to search for putative MYC binding sites in the regulatory regions of the b 4 gene. Two such sites were identified using the TESS software (Schug and Overton, 1997) . One site was found to be positioned in the 5 0 promoter region at position -1261/ À1256 while the other, at position þ 2457/ þ 2463, was located in a region functioning as an enhancer of ITGB4 (Takaoka et al., 1998) . We used a dual-luciferase reporter gene system to investigate if these putative MYC binding sites had any functional relevance for integrin b 4 expression by overexpressing ectopic MYC in conjunction with different b 4 promoter reporter plasmids in the colon carcinoma cell line Caco-2/15 (Figure 5a, b) . The effect of overexpressing MYC in the colon carcinoma cell line Caco-2/15 was first analysed with an artificial MYC responsive reporter plasmid, pMycTaLuc. As shown in Figure 5a , cotransfection of 
Discussion
The results show clear evidence that the expression of the integrin b 4 subunit is increased in WD and MD colon carcinomas and that in primary tumors as well as in adenocarcinoma cell lines, the b 4 form is distinct from the one found in normal proliferating intestinal cells. Furthermore, this increased expression is closely correlated with MYC transcript levels and this correlation is causal, since forced expression of MYC in a colon carcinoma cell line stimulates integrin b 4 promoter activity.
As for many other membrane proteins analysed, including the integrins, b 4 appears to be relatively well maintained in colon adenomas (Stallmach et al., 1992; Sordat et al., 1998; Lohi et al., 2000) . However, its expression in colon carcinomas appears more controversial, having been initially reported to either decrease (Stallmach et al., 1992) or increase (Falcioni et al., 1994) in well to PD stages. In a more recent study, b 4 was reported to gradually decrease in carcinomas, especially in PD areas (Sordat et al., 1998) , while another concluded that b 4 remains abundant and well polarized in carcinoma cells (Lohi et al., 2000) . These two latter studies (Sordat et al., 1998; Lohi et al., 2000) are in good agreement with the data presented herein since relatively high staining intensity was observed in both normal mucosa and WD and MD carcinomas. The inclusion of matched resection margins, used as controls for the estimation of the staining intensity, allowed us to identify an overall increase in the b 4 staining intensity in 10 of the 18 tested moderately and well-differentiated carcinomas. The downregulation of b 4 integrin subunit expression would thus appear to be a phenomenon exclusive to PD carcinomas (Sordat et al., 1998) .
Another finding of potential functional importance for colon cancer progression is the identification of the b 4 ctdÀ form in the normal colonic glands and its loss in colon cancer cells. The b 4 ctdÀ variant was first identified in the small intestinal epithelium as the predominant form of b 4 associated with the undifferentiated and proliferative crypt cell population (Basora et al., 1999) . Interestingly, the a 6 b 4 complex can assemble in cells expressing the b 4 ctdÀ variant but was found to be unable to mediate functional cell adhesion to its ligand laminin-5, emphasizing the potential importance of the cytoplasmic domain for the function of the molecule (Basora et al., 1999) . Herein, the use of the same immunological approach allowed us to identify the b 4 ctdÀ form in the lower half of the colonic gland in normal specimens. This suggests that in the colon, as in the small intestine, the b 4 ctdÀ form is related to the proliferative and less differentiated cells of the ctd þ form predominates in the mature and nonproliferating cells of the surface epithelium. In this context, the lack of b 4 ctdÀ expression in colonic cells in both primary carcinoma tumors and established adenocarcinoma cell lines is noteworthy. Biochemical analysis of b 4 in intestinal cells suggests that the cytoplasmic domain is subject to a cotranslational cleavage in crypt cells (Basora et al., 1999) . Based on the ubiquitous lack of b 4 ctdÀ in colon cancer cells, it could be speculated that the proteolytic activity responsible for the processing of b 4 in proliferative intestinal cells is either lost or downregulated throughout cancer progression.
Considering that the cytoplasmic domain appears to be important for intracellular signaling events (Nikolopoulos et al., 2004) and b 4 -mediated laminin interactions (Basora et al., 1999) , the expression of a predominant b 4 ctd þ form in colon cancer cells may be of functional relevance for cancer progression. Indeed, a key role for a 6 b 4 -mediated cell-laminin interactions in colon cancer cell invasion has been elegantly demonstrated by Mercurio's team ) as well as other laboratories (Dajee et al., 2003) over the last 10 years. Furthermore, expression studies have identified major alterations in laminin-5 distribution at the invasion fronts of primary colon cancers (Lohi et al., 2000) . In this context, our results demonstrating an increase in the levels of the b 4 subunit in colon cancer cells, taken together with the fact that it is expressed as a ctd þ form generating an a 6 b 4 complex which is functional for interaction with laminin-5, support the idea that the integrin b 4 subunit is involved in colon cancer progression through laminin interactions.
A significant increase of b 4 in colon carcinomas was also observed at the transcript level confirming the observations obtained by indirect immunofluorescence. Indeed, analysis of b 4 mRNA revealed an overall 2.0-to 2.5-fold increase in primary tumors compared with the respective controls, depending on the method used for evaluation. In comparison, an increase of 3.0-to 3.5-fold was denoted for the oncogene MYC. This latter observation is in good agreement with previous studies reporting an elevated expression of MYC in a significant proportion of colon cancers relative to the normal colonic mucosa (Erisman et al., 1985; Smith et al., 1993) . Interestingly, analysis of b 4 and MYC transcript levels in individual specimens revealed a close correlation suggesting that they could be functionally related. This potential relation was supported by the identification of MYC binding sites in the 5 0 region of the integrin b 4 subunit promoter that, as shown herein, are functional for MYC-dependent transcriptional upregulation of the integrin b 4 gene. Despite its profound impact on cellcycle regulation (Pelengaris et al., 2002) and association with colon carcinomas (Erisman et al., 1985; Smith et al., 1993) , MYC is a relatively weak activator of target gene expression, activating natural and artificial target promoters in the two-to five-fold range (Eisenman, 2001; Levens, 2002; Kim et al., 2003) . The 1.8-fold upregulation of an artificial MYC-responsive promoter upon co-transfection with MYC was therefore not surprising in the context of colon adenocarcinoma Caco-2/15 cells. The finding that MYC induces a 1.6-fold upregulation of integrin b 4 promoter activity in the same adenocarcinoma cell line was thus considered to be physiologically relevant. In support of this notion is the fact that we used the complete 5.5 kb b 4 promoter that has been shown to contain several transcriptional repressor sites in the -257 to À5197 bp region (Takaoka et al., 1998) . Complementary studies with other promoter constructs allowed us to determine that the MYC responsive element in the b 4 integrin promoter is located 5 0 to the transcriptional start site and is not part of the transactivating complex that stimulates b 4 transcriptional activity via an enhancer located in intron 1 of the b 4 gene (Takaoka et al., 1998) . It is interesting to note that a functional MYC binding site was previously identified in the integrin a 6 subunit promoter (Nishida et al., 1997) , thus supporting a role for MYC in the control of the expression of the integrin a 6 b 4 complex.
A consistent difficulty in MYC biology is the weak nature of target gene activation by MYC and the broad range of genes that can be activated or repressed by it (Levens, 2002; Pelengaris et al., 2002; Wanzel et al., 2003) , making it difficult to distinguish between the direct and indirect transcriptional effects of MYC. Thus, we cannot rule out the possibility that the observed effect of MYC on the activity of the integrin b 4 promoter is not in fact mediated directly by MYC but by a more downstream effect of MYC activity. It is, however, clear from our studies that in the cellular context of a colon carcinoma cell, overexpression of MYC leads to an upregulation of transcriptional activity of the b 4 integrin subunit promoter. Considering indications that activation of the integrins linked to the ras signaling pathways, such as a 6 b 4 (Wary et al., 1996) , leads to rapid induction of MYC and/or c-fos transcription and activation of cell proliferation (Dike and Farmer, 1988; Mainiero et al., 1997; Sanders et al., 1998) , the possibility of the existence of a positive feedback loop where MYC would stimulate b 4 expression, which would subsequently, via the ras signaling pathway, stimulate MYC expression, remains a possibility.
Materials and methods
Tissues and cell lines
Samples of adult colon were obtained from 22 patients between the ages of 49 and 86 years who had undergone surgical treatment for colon adenocarcinoma. For each patient, samples from the primary tumor and from nondiseased areas (at least 10 cm distant from the lesion) corresponding to the resection margin were obtained. Diagnoses of adenocarcinoma were confirmed by pathologists. Staging of the carcinomas according to Astler and Coller (1954) was as follows: two WD (B2), 16 MD (B2) and four PD (1 B2 and 3 C2). The project was in accordance with a protocol approved by the local Institutional Human Research Review Committee for the use of human material. All tissues were processed within 1 h of surgery. The preparation and embedding of tissues for cryosectioning was performed as described previously (Beaulieu, 1992; Beaulieu and Vachon, 1994) . Five of these paired specimens (1 WD, 3 MD and 1 PD) were also available for RNA extraction. A second series of four paired samples (resection margin and confirmed MD adenocarcinomas) was obtained from the Cooperative Human Tissue Network (Midwestern Division, Ohio State University, OH, USA). These additional samples were only used for RNA extraction.
The colon carcinoma cell lines used were the Caco-2/15, a clone of the Caco-2 cell line (Chantret et al., 1988) characterized elsewhere (Beaulieu and Quaroni, 1991; Vachon and Beaulieu, 1992 ) and used at 5 days postconfluence, HT29(G), T84, LoVo, Colo201 and HCT116, which were grown according to instructions provided by the ATCC (Rockville, MD, USA) and used at 80-90% confluence. The HT29(I) cells (partially differentiated) were obtained after selection in a glucose (G)-free medium containing 2.5 mM inosine for six passages, as described previously (Beaulieu et al., 1989) . Finally, a normal human intestinal crypt-like cell line, HIEC, which has been previously characterized for its exclusive expression of a truncated cytoplasmic terminal domain form of the b 4 integrin subunit (b 4 ctdÀ ) (Basora et al., 1999) , was also included.
Immunodetection methods
For indirect immunofluorescence, cryosections 2-3 mm thick were cut on a Jung Frigocut 2800N cryostat (Leica Canada, Saint-Laurent, Que´., Canada) and fixed in methanol (10 min, À201C) before immunostaining as described elsewhere (Beaulieu, 1992; Beaulieu and Vachon, 1994) . Four distinct antibodies for the detection of the b 4 subunit in indirect immunofluorescence were used in this work. An anti-b 4 antiserum (Giancotti et al., 1992) raised against the last 31 amino acids of the cytoplasmic terminal domain was the kind gift of Dr E Ruoslahti (The Burnham Institute, La Jolla, CA, USA). Another anti-b 4 antiserum (AB1922; Chemicon International, Mississauga, ON, Canada) directed against the last 20 amino acids of the cytoplasmic terminal domain was also available. These two antibodies are hereafter referred to as the anti-b 4 c (anti-b 4 cytoplasmic) antibodies. The monoclonal antibodies 3E1 (Hessle et al., 1984) (Life Technology Inc., Burlington, ON, Canada) and 439-9B (Pharmingen, Mississauga, ON, Canada), both raised against epitopes on the extracellular domain of the b 4 subunit, were also used. These two antibodies will hereafter be referred to as the anti-b 4 e (anti-b 4 extracellular) antibodies. For the double staining procedure, combinations of the two anti-b 4 c and anti-b 4 e antibodies were used. Primary anti-b 4 c antibodies were diluted 1/100 while the anti-b 4 e antibodies were used at 5 mg/ml. The secondary antibodies were fluorescein isothiocyanate-conjugated goat anti-rabbit IgG and rhodamine-conjugated goat anti-mouse IgG. Sections were stained with Evan's blue (0.01% in PBS), mounted in glycerol : PBS (9 : 1) containing 0.1% paraphenylenediamine and viewed with a Reichert Polyvar 2 microscope (Leica Canada, Saint-Laurent, QC, Canada) equipped for epifluorescence. In all cases, no immunofluorescent staining was observed when a mix of mouse and rabbit nonimmune sera replaced primary antibodies.
Western blot analyses were performed as previously described (Beaulieu et al., 1989; Vachon and Beaulieu, 1995) . Briefly, proteins (100 mg/lane) were separated by SDS/12% PAGE under reducing conditions and transferred onto nitrocellulose (BioRad, Mississauga, ON, Canada). Membranes were blocked 2 h at room temperature in PBS containing 10% blotto and incubated overnight with the mouse monoclonal antibody Clone 7 (BD Transduction Laboratories, Mississauga, ON, Canada) directed against the wild-type b 4 form and used at a 1 : 1000 dilution in PBS-blotto. After extensive washing in PBS, membranes were processed for enhanced chemiluminescence (ECL system; Amersham/Pharmacia Biotech., Baie D'Urfe´, QC, Canada), according to the manufacturer's instructions. Then, membranes were stripped of antibodies in a 100 mM glycineÀ1% Tween solution (pH 2.9, 30 min at room temperature), washed in PBS, re-blocked and re-probed with the rabbit anti-b 4 c, specifically reacting with the ctd domain as described above, and processed for chemiluminescence. HIEC cell extracts, containing only the b 4 ctdÀ variant of b 4 , were used as control for the specificity of the dual probing. Secondary donkey anti-rabbit IgG and sheep anti-mouse IgG antibodies conjugated to horseradish peroxidase were from Amersham Bioscience UK Limited (Little Chalfont, Buckinghamshire, England).
RNA extraction and reverse transcriptase-PCR
Total RNAs from sets of paired carcinoma specimens were prepared according to Clontech's Atlas Total RNA Isolation protocol (Clontech, Palo Alto, CA, USA) and stored in RNAsecure (Ambion, Austin, TX, USA) at À801C. The integrity of the RNA was verified by ethidium bromide staining of agarose gel migrations and quantities were determined spectrophotometrically. First-strand cDNA synthesis using Omniscript (Qiagen, Mississauga, ON, Canada) was performed on 2 mg total RNA using oligo(dT) 12À18 (Amersham Pharmacia, Baie d'Urfe´, QC, Canada) as primer. Conditions for amplification of b 1 , b 4 , and sucrase-isomaltase have been described previously (Basora et al., 1999) . For MYC, we used the sense primer 5 0 -TACCCTCTCAACGACAGCAGCT CGCCCAACTCCT-3 0 and the antisense primer 5 0 -TCTTGA CATTCTCCTCGGTGTCCGAGGACCT-3 0 , which amplified a 477 bp amplicon at nucleotides 1147-1624 (Watt et al., 1983) . The human b-actin primer set for PCR (Stratagene, Cedar Creek, TX, USA) amplified a 661 bp fragment. Single stranded cDNA was amplified by Touchdown PCR (Don et al., 1991) in PCR buffer (Qiagen) containing 0.2 mM of both sense and antisense primers in the presence of 200 mM dNTPs and 2.5 U of Taq (Qiagen) for 24 cycles of denaturation (1 min at 941C), annealing (1 min at 651C declining by 11C every second cycle to 541C) and extension (2 min at 721C) in a thermal cycler (Perkin-Elmer DNA Thermal Cycler Model 480). MYC, b 1 and b 4 were amplified by an additional 4, 6 and 10 cycles, to annealing temperatures of 52, 51, and 501C, respectively. b-actin amplifications were used as controls to normalize the amounts of input RNA.
Real-time QPCR
Quantitative PCR was performed in an Mx3000P real-time PCR system (Stratagene, Cedar Creek, TX, USA) using SYBRGreen technology. The 2xSYBR s Green QPCR Master Mix was obtained from Stratagene (Cedar Creek, TX, USA) and mixed with the appropriate primers and high quality sterile water. All primers used for RT-QPCR were the same as for semiquantitative RT-PCR analysis except the primer pairs for MYC and integrin b 1 . The sequences for these primers were as follows: MYC-F: 5 0 -CCTACCCTCTCAACGACAGC, MYC-R: 5 0 -CTCTGACCTTTTGCCAGGAG and IntB1-F: 5 0 -CATCTGCGAGTGTGGTGTCT, IntB1-R: 5 0 -CATCTGC GAGTGTGGTGTCT. The primers for RPS14 have been described previously (Basora et al., 1999) .
All reactions were run using a standard program of the Mx3000P; 10 min of Taq activation at 951C, followed by 40 cycles of denaturation (951C, 1 min), primer annealing (571C, 1 min) and extension (721C, 1 min) ending with a melting curve analysis to validate the specificity of PCR products. Fluorescence data were acquired after the annealing step.
Amplification efficiencies were calculated as previously described (Escaffit et al., 2005) and assessment of differences in gene expression between controls and samples (resection margins and cancers) were calculated using two different approaches; the 'DDCt' approach (Applied Biosystem, ABI Prism 7700 Sequence Detection System, User Bulletin #2) and the 'R ¼ ðE target Þ DCt target =ðE reference Þ DCt reference ' approach (Pfaffl, 2001 ). The two methods yielded essentially similar results. Final results are expressed as fold difference of expression between resection margins and primary cancers. All amplicons yielded specific peaks during melting curve analysis with negligible unspecific amplification and had amplification efficiencies (E) between 1.903 and 1.948.
Plasmid constructs
A vector containing the coding sequence of MYC was a generous gift of Dr J Bartek (Department of Cell Cycle and Cancer and Apoptosis Laboratory, Institute of Cancer Biology, Danish Cancer Society, Copenhagen, Denmark). The MYC coding sequence was excised from this vector using the restriction enzymes XbaI and NotI (New England BioLabs, Mississauga, ON, Canada) and isolated on an ethidium bromide stained 1.5% agarose gel. After gel purification using the QIAEX II kit (Qiagen, Mississauga, ON, Canada) the XbaI/NotI fragment was ligated into XbaI/NotI digested pcDNA3.1( þ ) (Invitrogen, Burlington, ON, Canada) and named pcDNAMYC. Correct orientation and fidelity were confirmed by subsequent sequencing at the sequencing core facility of the Faculty of Medicine, University of Sherbrooke. The expression of MYC by pcDNAMYC was confirmed by Western blot of transiently transfected Caco-2/15 cells (data not shown).
A deletion mutation in the MYC coding sequence of pcDNAMYC leading to a reading frame shift at amino-acid 252 and subsequent premature termination of translation at amino-acid 257 was generated by PCR and named pcDNAD MYC. This deletion mutant lacks the COOH-terminal dimerization motif and is therefore DNA binding incompetent (Lavigne et al., 1998) . The three firefly luciferase reporter plasmids L5.5K, L5.5K-F and I5-F carrying 5.2 kb of the 5 0 promoter region of integrin b 4 with and without the enhancer located in intron 1 (Takaoka et al., 1998) were a kind gift of Drs T Yamada and S Hirohashi from the National Cancer Center Research Institute, Tokyo, Japan. A MYC responsive luciferase reporter plasmid (pMycTaLuc), carrying six MYC binding sequences in front of the minimal TATA box from the herpes simplex thymidine kinase (HSV-TK) promoter was from Clontech (BD Bioscience Clontech, Palo Alto, CA, USA).
Transfection and luciferase measurements
Caco-2/15 cells were seeded in 24-well plates (Falcon, Franklin Lakes, NJ, USA) and grown to 90-100% confluence before being transiently transfected in serum-free medium using FuGENE transfection agent (Roche, Indianapolis, IN, USA) in a mg DNA to ml transfection agent ratio of 1 : 9. Cells were kept under normal growth conditions after transfection (Dulbecco's modified Eagle medium supplemented with 2 mM GlutaMax I (GIBCO Invitrogen Corporation, Grand Island, NY, USA), 10 mM HEPES (GIBCO Invitrogen) and 10% FBS (ICN Biomedicals, Aurora, OH, USA)).
To establish an internal control of transfection efficiency, all transfections were performed as cotransfections using a renilla luciferase expression plasmid. Promoter activity was thus expressed using arbitrary units; firefly/renilla. The number of copies of CMV promoters in control transfections (empty vector -pcDNA 3.1) was kept equal to the experimental (MYC and DMYC) values by adjusting the absolute number of plasmids measured by micrograms. DNA concentrations in transfections were kept constant by the addition of pBluescript SK þ (Stratagene, Cedar Creek, TX, USA). Firefly and renilla luciferase activity was measured using the Dual-Luciferase s Reporter Assay System (Promega Corporation, Madison, WI, USA), according to the manufacturer's protocol using an EG&G Berthold MiniLumat LB 9506 for detection of chemiluminiscent signal.
Statistical analysis
Staining intensity of immunoflourescence on primary colon carcinomas was assessed independently by two researchers on a -to þ þ þ þ scale and subsequently converted to numeric values for statistical analytic purposes ('À': 0, ' þ ': 1, ' þ þ ': 2, ' þ þ þ ': 3, ' þ þ þ þ ': 4) and processed by the MannWhitney rank sum test for significant differences. Differences in firefly luciferase activity in the promoter activity assays were evaluated by the Tukey one-way ANOVA test. A paired t-test was used to evaluate differences in transcript levels of MYC and b 4 in cancer samples and resection margins. Analysis of correlation was performed using Pearson Product Moment Correlation, and regression analysis was performed using a standard regression analysis. All tests are two-sided and Po0.05 was considered significant in all experiments.
Analysis of the regulatory region of the integrin b 4 gene
A search for putative MYC binding sites in the 5 0 promoter region and in intron 1, which contains an enhancer of the integrin b 4 gene (Takaoka et al., 1998) , was conducted using the TESS software (Schug and Overton, 1997) 
